Skip to content

Withdraw due to duplicate registration. The clinical study for cerebral functional remodeling in patients with traumatic amputation

The clinical study for cerebral functional remodeling in patients with traumatic amputation

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025882
Enrollment
Unknown
Registered
2019-09-12
Start date
2019-10-01
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

traumatic amputation

Interventions

Intervention group:oral oxycodone (10 mg) and acetaminophen (650 mg)
Control group:acetaminophen (650 mg) only

Sponsors

Shanghai Jiaotong University Affiliated Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Aged from 18 to 100 years, male or female is not limited; 2. Diagnosis of acute limb fracture less than one day after injury; 3. Location of fractures including foot, ankle, tibia, fibula, knee, femur, hip, hand, wrist, forearm, elbow, humerus, shoulder and clavicle; 4. Indicated for nonoperative treatment; 5. And willing to participated in this study.

Exclusion criteria

Exclusion criteria: 1. Patients with non-limb fractures; 2. Patients who have multiple fractures involving more than one site; Patients patients with vascular, nerve, or tendon injuries; 3. Open fractures; 4. Patients with a pre-injury chronic condition requiring frequent pain management such as sickle cell disease, fibromyalgia, or any neuropathy; 5. Patients who have taken methadone at any time in their life; 6. Patients who report any adverse reaction; 7. Patients who are allergic to any of the study medications; Patients who have contraindications, such as peptic ulcer disease, or who report any prior use of recreational narcotics; 8. Medical conditions that might affect metabolism of opioid analgesics or acetaminophen, such as hepatitis, renal insufficiency or failure, hypo- or hyperthyroidism, and Addisons or Cushings disease; 9. Taking any medicine that might interact with any of the study medications, such as anticholinergic drugs, oral contraceptives, loop diuretics, probenecid, or liver enzyme inducers; 10. Unable to communicate properly and answer questions (e.g., patients with a diagnosis of dementia); 11. Physically handicapped people with mobility problems; 12. People with no fixed domicile and short-term visitors who cannot be easily located; 13. Patients who are pregnant, verified by urine or serum HCG testing; 14. People unwilling or unable to cooperate with data collectors or researchers.

Design outcomes

Primary

MeasureTime frame
NRS score;

Secondary

MeasureTime frame
SAS score;SDS score;EQ-5d;the patient’s satisfaction with the medication (0-10);change in the quality and duration of sleep;number of study medications used;duration that analgesics were taken;adverse events;

Countries

China

Contacts

Public ContactXianyou Zheng

Shanghai Jiaotong University Affiliated Sixth People's Hospital

zhengxianyou@126.com+86 13916180968

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026